Molecular pathogenesis of pancreatic cancer

Anirban Maitra, Scott E Kern, Ralph H Hruban

Research output: Contribution to journalArticle

Abstract

Pancreatic cancer is fundamentally a disease of inherited and acquired mutations in cancer-related genes. The genes targeted in pancreatic cancer include tumor-suppressor genes (p16/CDKN2A, TP53 and SMAD4), oncogenes (KRAS, BRAF, AKT2, MYB, and AIB1), and genome-maintenance genes (MLH1, MSH2, BRAC2 and other Fanconi anemia genes). An understanding of the cancer-related genes that are altered in pancreatic cancer has a number of clinical applications including genetic counseling for individuals with a family history of cancer, early detection of pancreatic neoplasia, and mechanism-based therapies for patients with advanced disease. This chapter will provide an overview of the molecular pathogenesis of pancreatic cancer with emphasis on clinical applications.

Original languageEnglish (US)
Pages (from-to)211-226
Number of pages16
JournalBest Practice and Research: Clinical Gastroenterology
Volume20
Issue number2
DOIs
StatePublished - Apr 2006

Fingerprint

Pancreatic Neoplasms
Neoplasm Genes
Genes
Fanconi Anemia
Genetic Counseling
Tumor Suppressor Genes
Oncogenes
Early Detection of Cancer
Maintenance
Genome
Mutation
Neoplasms
Therapeutics

Keywords

  • Familial aggregation
  • Oncogene
  • Pancreatic cancer
  • Screening
  • Treatment
  • Tumor-suppressor gene

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Molecular pathogenesis of pancreatic cancer. / Maitra, Anirban; Kern, Scott E; Hruban, Ralph H.

In: Best Practice and Research: Clinical Gastroenterology, Vol. 20, No. 2, 04.2006, p. 211-226.

Research output: Contribution to journalArticle

@article{2325cd9b999a4aca8d12c9a772f76c55,
title = "Molecular pathogenesis of pancreatic cancer",
abstract = "Pancreatic cancer is fundamentally a disease of inherited and acquired mutations in cancer-related genes. The genes targeted in pancreatic cancer include tumor-suppressor genes (p16/CDKN2A, TP53 and SMAD4), oncogenes (KRAS, BRAF, AKT2, MYB, and AIB1), and genome-maintenance genes (MLH1, MSH2, BRAC2 and other Fanconi anemia genes). An understanding of the cancer-related genes that are altered in pancreatic cancer has a number of clinical applications including genetic counseling for individuals with a family history of cancer, early detection of pancreatic neoplasia, and mechanism-based therapies for patients with advanced disease. This chapter will provide an overview of the molecular pathogenesis of pancreatic cancer with emphasis on clinical applications.",
keywords = "Familial aggregation, Oncogene, Pancreatic cancer, Screening, Treatment, Tumor-suppressor gene",
author = "Anirban Maitra and Kern, {Scott E} and Hruban, {Ralph H}",
year = "2006",
month = "4",
doi = "10.1016/j.bpg.2005.10.002",
language = "English (US)",
volume = "20",
pages = "211--226",
journal = "Bailliere's Best Practice and Research in Clinical Gastroenterology",
issn = "1521-6918",
publisher = "Bailliere Tindall Ltd",
number = "2",

}

TY - JOUR

T1 - Molecular pathogenesis of pancreatic cancer

AU - Maitra, Anirban

AU - Kern, Scott E

AU - Hruban, Ralph H

PY - 2006/4

Y1 - 2006/4

N2 - Pancreatic cancer is fundamentally a disease of inherited and acquired mutations in cancer-related genes. The genes targeted in pancreatic cancer include tumor-suppressor genes (p16/CDKN2A, TP53 and SMAD4), oncogenes (KRAS, BRAF, AKT2, MYB, and AIB1), and genome-maintenance genes (MLH1, MSH2, BRAC2 and other Fanconi anemia genes). An understanding of the cancer-related genes that are altered in pancreatic cancer has a number of clinical applications including genetic counseling for individuals with a family history of cancer, early detection of pancreatic neoplasia, and mechanism-based therapies for patients with advanced disease. This chapter will provide an overview of the molecular pathogenesis of pancreatic cancer with emphasis on clinical applications.

AB - Pancreatic cancer is fundamentally a disease of inherited and acquired mutations in cancer-related genes. The genes targeted in pancreatic cancer include tumor-suppressor genes (p16/CDKN2A, TP53 and SMAD4), oncogenes (KRAS, BRAF, AKT2, MYB, and AIB1), and genome-maintenance genes (MLH1, MSH2, BRAC2 and other Fanconi anemia genes). An understanding of the cancer-related genes that are altered in pancreatic cancer has a number of clinical applications including genetic counseling for individuals with a family history of cancer, early detection of pancreatic neoplasia, and mechanism-based therapies for patients with advanced disease. This chapter will provide an overview of the molecular pathogenesis of pancreatic cancer with emphasis on clinical applications.

KW - Familial aggregation

KW - Oncogene

KW - Pancreatic cancer

KW - Screening

KW - Treatment

KW - Tumor-suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=33645050942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645050942&partnerID=8YFLogxK

U2 - 10.1016/j.bpg.2005.10.002

DO - 10.1016/j.bpg.2005.10.002

M3 - Article

C2 - 16549325

AN - SCOPUS:33645050942

VL - 20

SP - 211

EP - 226

JO - Bailliere's Best Practice and Research in Clinical Gastroenterology

JF - Bailliere's Best Practice and Research in Clinical Gastroenterology

SN - 1521-6918

IS - 2

ER -